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Background:
Little is known about the influence of ketamine and its enantiomers on cerebral haemodynamics, and directly comparable reports are lacking. This study was designed to evaluate cerebrovascular responses to bolus infusions of racemic, S(+)-and R(-)-ketamine in an established experimental model. To date no systematic study has been carried out regarding the cerebral haemodynamic effects of racemic ketamine and its enantiomers. The present study was designed to evaluate and compare, in the same animals, cerebral and systemic haemodynamic responses to sequential intravenous (iv) equipotent bolus infusions in random order of each of these three ketamine compounds.
Methods

Materials and methods
The experiments were carried out at the Department of Experimental Research, Malmö University Hospital, after approval of the study design by the Medical Ethics Committee on Animal Studies, Lund University, Malmö, Sweden.
Animals
Fourteen juvenile domestic pigs (Swedish landrace/Yorkshire/Hampshire) weighing (mean ± SD) 23.6 ± 2.3 kg, were used in two series of eight (part I) and six (part II) animals. The animals were kept in laboratory stables and deprived of food overnight but had free access to water.
Anaesthesia
Anaesthesia was induced with intravenous (iv) propofol 4-6 mg 
Cerebral haemodynamics and metabolism
Surgical preparation has been reported in detail elsewhere (2 
Systemic and pulmonary haemodynamics
A 20 G 45 mm teflon catheter (Intraflow, Viggo AB, Helsingborg, Sweden) was inserted in the right femoral artery and used for invasive pressure measurements and blood sampling.
Heparin 250 IU . kg -1 iv was given soon after all catheters had been inserted, and their correct positions were verified at autopsy.
Study drugs
The commercially available racemic ketamine (Ketalar 
Doses
Previously, the induction dose of racemic ketamine (10 mg 
Blood concentrations
Blood for analysis of racemic, S-and R-ketamine and of norketamine was drawn at 1, 10 and 40 min after each bolus infusion of study drug. Drug concentrations were assayed in haemolysed blood by gas liquid chromatography (6) .
Experimental design
To evaluate the experimental model designed for comparison of different drugs in the same animal, three identical iv 60-second bolus infusions of racemic ketamine were first given in each animal of the first series (part I, n=8), and the pharmacodynamic responses were compared. After that the racemate was compared to its two enantiomers in randomised order in each animal of the second series (part II, n=6).
The approximately 90-minute period of surgical preparation was followed by a 60-minute wash-out of desflurane. The three series of measurements in part I and in part II lasted for approximately 150 min (Fig. 1 ).
In the part I experiment, an iv bolus dose of racemic ketamine, 10.0 mg . kg -1 , was given over 60 s with determinations of CBF and systemic haemodynamic variables at 1, 5, 10, 15 and 30 min after the start of infusion. A second and a third bolus dose of study drug were given and the effects studied accordingly after approximately 45 and 90 min, respectively, from the first infusion ( Fig. 1 ). min from the start of each infusion. The second and third bolus infusions were given 3-5 min after completion of the preceding measurement period (Fig. 1) .
After each experiment the animal was given an iv overdose of pentobarbital, and adequate positions of all catheters were verified at autopsy.
Statistical considerations
Values in text and tables are given as median with 25 th and 75 th percentiles in parenthesis when not stated otherwise. Percentages were calculated from the mean values.
In part I, maximal (one-minute value) and average (area under curve) changes in CBF after each of the three bolus infusions were compared to detect any acute tolerance to repeated administration of racemic ketamine. Systematic and random errors were defined as the mean and standard deviation, respectively, of differences in CBF change between the second and first and between the third and second infusions.
Student`s t-test was used for analysis of parametric data and the Mann-Whitney U-test was used for unpaired analysis of non-parametric data. One-way analysis of variance (ANOVA) with repeated design was used to detect differences in response over time of and between the study drugs. To avoid mass significance, posthoc analysis was made with correction according to Bonferroni, and no comparisons between study drugs at different time points
were made. A P-value of 0.05 or less was considered as statistically significant.
Results
Part I
Blood concentrations of racemic ketamine and corresponding levels of the main metabolite norketamine are given in Table 1 .
[ 
[TABLE 2 NEAR HERE]
Cerebral and systemic physiological effects of racemic ketamine were evaluated for all three bolus infusions together, since they did not differ significantly from each other.
Changes in CVRe were biphasic with a 1-minute increase by 7.0% and a 10-minute decrease by 33%, and the MAP was reduced by 38% at 1 min (Table 2) . The duration of clinical effect, i.e. maintenance of lateral recumbent position, were for Sketamine 9.7 ± 3.4 min and for R-ketamine 12 ± 4.6 min (P=0.093).
Part II
Accordingly, comparable iv induction doses of S-, racemic and R-ketamine were 5, 10 and 20 mg . kg -1 with respect to cerebral effects in this and previous (2) studies.
Blood concentrations of racemic ketamine, S-ketamine, R-ketamine and the main metabolite norketamine in part II are shown in Table 1 .
Cerebral blood flow and vascular resistance
The effect on CBF over time was significant for S-ketamine (P=0.036) and racemic ketamine (P=0.001) but not for R-ketamine (P=0.10), with initial 22% decreases at 1 and 5 min for racemic ketamine, and a biphasic response pattern including a 19% decrease at 1 min followed by a 12% increase at 15 min for S-ketamine. The responses in CBF differed significantly between S-and R-ketamine (P<0.001) and between S-and racemic ketamine (P<0.001) but not between racemic and R-ketamine (P>0.30) (Fig. 2 ).
There was no significant effect on CVRe over time for any study drug (S-ketamine P=0.16, racemic ketamine P=0.29 and R-ketamine P=0.083), and no difference in effect between the study drugs (P>0.30).
No study drug increased the CavO 2 by more than 10% and there was no significant effect in CavO 2 over time for any study drug (P>0.30). Infusion of S-ketamine was associated with significantly lower CavO 2 than of R-ketamine (P=0.016) or racemic ketamine (P=0.008) but there was no difference in effect between R-ketamine and racemic ketamine (P>0.30) (Fig. 2) .
[FIGURE 2 NEAR HERE]
Systemic haemodynamics
All three study drugs had significant effects on MAP over time (S-ketamine P=0.005, racemic ketamine P<0.001, R-ketamine P<0.001) with maximal reductions by 11% for Sketamine and 18% for racemic ketamine at 5 min, and by 31% for R-ketamine at 1 min. The response in MAP to S-ketamine differed from those to R-ketamine (P<0.001) and racemic ketamine (P<0.001), but there was no difference in response between R-ketamine and racemic ketamine (P>0.30) (Fig. 2) .
Other physiological variables
Median core temperature was 37.8 (37.1; 38.6)°C in part I and 38.5 (38.3; 38.6)°C in part II.
Discussion
Our main findings of smaller decreases in cortical CBF and systemic MAP by S-ketamine than by racemic or R-ketamine in equipotent anaesthetic doses -indicating more stable cerebral and systemic haemodynamics -have not been reported previously.
Earlier studies in volunteers and patients have shown similar systemic heamodynamic reactions to S-ketamine and to racemic ketamine at the same dosage ratio as used by us (7) (8) (9) (10) (11) . A confounding factor in those studies could be the simultaneous administration of midazolam, which might have attenuated differences in effect between the ketamine compounds.
The initial depression of cerebral and systemic haemodynamics found here probably results from a direct effect of ketamine and its enantiomers and from attenuation of their with a recent hypothesis that changes in CBF are determined by changes in the cerebral metabolic rate for glucose rather than in the CMRO 2 (25, 26) .
The similarity in CBF response between the three injections of racemic ketamine in part I of the study implies lack of cerebral acute-tolerance to ketamine allowing repeated bolus doses of racemic ketamine and its enantiomeres to be evaluated accordingly in part II. Although carry-over or order effects cannot be statistically excluded due to the limited number of animals, they are unlikely considering the randomised cross-over study design. In part I the CBF returned completely to the baseline level before the next injections of racemic ketamine, whereas the MAP did not, possibly because the time between injections was too short, particularly after injection of R-ketamine as further discussed below.
The doses are crucial when comparing effects of anaesthetic drugs. In the present experiments, the study drugs were compared in equianaesthetic doses obtained from the recumbency tests indicating a dose ratio of 1:3.8 between S-and R-ketamine. This ratio in the pig is close to that of 1:4 reported in humans in the early eighties (27, 28) . Anaesthetic equipotency of these doses is further supported by their similar decreases in CBF at the oneminute measurements. This is also in conjunction with earlier work, where the NMDA receptor affinity of S-ketamine has been shown to be three to four times higher than that of Rketamine in humans (5) . These results are all in accordance with the theory of NMDA receptors as main cerebral targets of action for racemic ketamine and its enantiomeres (29) .
In contrast, the difference in initial effect on MAP between the study drugs in these doses indicates that systemic haemodynamic effects of ketamine and its enantiomers are nonspecific and probably also involve receptors other receptors. The pharmacodynamic aspects of the ketamine compounds are complex, and they interact not only with NMDA receptors but also with i.a. glutamate, nicotinic and muscarinic cholinergic, mono-aminergic, sigma and opioid receptors (30) . However, the affinity of ketamine and its enantiomers for these receptors is 10-20 times lower than for NMDA receptors. Differences in the duration of effects on CBF and on MAP of the study drugs might partly be explained by differences in target receptors between the cerebral and the systemic circulation.
The haemodynamic effects could also at least in part be due to differences in their pharmacokinetic properties, since differences in drug load, and hence in need for metabolising capacity, between racemic, S-and R-ketamine are two-to fourfold.
The concentration of R-norketamine, the main metabolite of R-ketamine, has been shown to be up to three times higher than that of S-norketamine in brain tissue after administration of the same doses of R-and S-ketamine (31) . The main metabolite, norketamine, with a onethird to one-fifth potency of the racemate (30), was found to reach blood peak levels of 3 µg . ml -1 with possible, but probably little, sustained influence on systemic and cerebral haemodynamics.
The relative plasma concentration ratio between study drug and main metabolite at 40 min was below 1:2 for S-ketamine and close to 1:1 for both racemic and R-ketamine.
Nevertheless, the 40-minute CBF value had returned to baseline for S-ketamine but not so for R-or racemic ketamine (Table 2 ). A difference in CBF level at 40 min between S-and Rketamine could have resulted from the four times higher dose of R-ketamine considering the similar pharmacokinetic properties of the enantiomers (27, 28) .
Conclusion
S(+)-ketamine was associated with less cerebral and systemic haemodynamic depression than racemic or R(-)-ketamine in equipotent doses in this experimental model. These findings indicate potential advantages of S-ketamine over racemic ketamine. Blood concentrations of racemic ketamine, S-ketamine, R-ketamine and norketamine during part I (n=8) and II (n=6) in normoventilated pigs anaesthetized with fentanyl and vecuronium.
Legends
Data is reported as median with 25 th and 75 th percentiles in paranthesis. 
